Navigation Links
Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
Date:5/20/2010

INDIANAPOLIS, May 20 /PRNewswire-FirstCall/ -- Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer.(1)  Study results will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. on June 6, 2010.

"While great strides have been made in treating some cancers over the past decade, others – such as melanoma – continue to be challenging to treat," said John M. Kirkwood, M.D., co-leader of the Melanoma Program of the University of Pittsburgh Cancer Institute.  "Ongoing research is critical if we are to find appropriate treatments for patients who need them most."  

The Phase II study (Abstract #8541) evaluated the use of tasisulam as a second-line treatment in patients with unresectable or metastatic melanoma.  The trial's primary objective was to determine overall response rate and its two secondary objectives were to determine progression-free survival and overall survival.  Of the 68 patients enrolled in the study, eight demonstrated partial response, 24 had stable disease (no progression after two cycles), 25 had progressive disease, and 11 did not have their disease progression completely evaluated.  The median progression-free survival was 2.6 months and the median overall survival was 9.6 months.  

Tasisulam was given in 21-day cycles using a dosing algorithm based on body weight.  The most common grade 3/4 hematologic toxicities were thrombocytopenia (low platelet count), neutropenia (low white blood cell count) and anemia (
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations
2. Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
3. Lillys Online, Interactive Health Education Program Receives Two Web Awards
4. Lilly Reports Fourth-Quarter and Full-Year 2009 Results
5. Lilly Confirms Date and Conference Call For Fourth-Quarter and Full-Year 2009 Financial Results Announcement
6. Lilly CEO Stresses Human Element in Driving Medical Innovation
7. Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
8. PDL BioPharma Announces New Licensing Agreement With Eli Lilly
9. Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies
10. Lilly CFO Derica Rice Assumes Expanded Responsibilities, Promoted to Executive Vice President
11. Lilly Declares First-Quarter 2010 Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... SAN JOSE, California , 2 marzo 2015 ... che ha aperto la strada alla fusione con ... dell,articolazione sacroiliaca (SI) con iFuse Implant System ® ... iFuse sono stati eseguiti nel mondo intero utilizzando ... tecnica chirurgica iFuse viene sempre più adottata guadagnando ...
(Date:3/2/2015)... March 2, 2015 Shire plc (LSE: ... company has submitted a New Drug Application (NDA) with the ... lifitegrast for the treatment of signs and symptoms of dry ... be the first treatment indicated to address both the signs ... which affects millions of people," said Philip J. Vickers ...
(Date:3/2/2015)... N.J. and BETHESDA, Md. ... development-stage immunotherapy company focused on treating and preventing autoimmune ... 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen (NASDAQ: ... exclusive license agreement, Celimmune has the rights to develop, ... excluding Japan . Concurrently, Amgen has ...
Breaking Medicine Technology:SI-BONE, Inc. rivela l'obiettivo di 15.000 interventi con iFuse 2SI-BONE, Inc. rivela l'obiettivo di 15.000 interventi con iFuse 3SI-BONE, Inc. rivela l'obiettivo di 15.000 interventi con iFuse 4Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults 2Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults 3Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults 4Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 2Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 3
... SAN DIEGO, Jan. 9, 2012 Amylin Pharmaceuticals, Inc. (Nasdaq: ... for 2012, with a strong focus on driving the global ... presentation at the 30th Annual J.P. Morgan Healthcare Conference in ... Bradbury highlighted steps the company is taking to prepare for ...
... 9, 2012   Remedi SeniorCare , one of the ... skilled nursing, assisted living and retirement communities, announced that ... only long-term care pharmacy to have its electronic order ... Pharmacy for electronic prescribing.  "This is ...
Cached Medicine Technology:Amylin Outlines Corporate Strategy to Maximize Global Value of Diabetes Franchise and Advance Key Pipeline Candidates 2Amylin Outlines Corporate Strategy to Maximize Global Value of Diabetes Franchise and Advance Key Pipeline Candidates 3Amylin Outlines Corporate Strategy to Maximize Global Value of Diabetes Franchise and Advance Key Pipeline Candidates 4Remedi SeniorCare® Wins Ohio State Board of Pharmacy's First and Only Approval for Electronic Prescribing in State of Ohio 2
(Date:3/2/2015)... The Workgroup for Electronic Data Interchange (WEDI), the ... IT to create efficiencies in healthcare information exchange, released ... The white paper by WEDI’s ICD-10 Testing Subworkgroup provides ... by focusing on primary considerations and steps for external ... 1, 2015 implementation date. Download the white paper ...
(Date:3/2/2015)... The minimally invasive surgical instruments ... of 6.1% to reach $14,133.0 million by 2019 ... such as advantages of minimally invasive surgeries over ... minimally invasive surgeries and increasing number of surgical ... global minimally invasive surgical instruments market. , For ...
(Date:3/2/2015)... 02, 2015 Dinner preparation and ... to the success of DinnerDork , a ... and delicious for thousands of busy customers. The ... by expanding to offer a total of 6 ... seasonally appropriate classic recipes and comfort foods; Paleo ...
(Date:3/2/2015)... Regulatory Compliance Associates® Inc. (RCA), ... and technical consulting, announces Mr. Seyed Khorashahi has ... , Before joining RCA, Mr. Khorashahi had over ... all aspects of developing safety-critical medical devices. ... Regulatory Compliance Associates Inc., Baxter Healthcare, and Beckman ...
(Date:3/2/2015)... March 02, 2015 What are the ... physicians request references? When are interviews scheduled, how can ... opportunities?, Both training and practicing physicians who are looking ... questions and more at the PracticeLink Physician Career Advancement ... drop-in Job Fair is from 5:30 to 8:30 p.m. ...
Breaking Medicine News(10 mins):Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 3Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2
... Study finds twice the incidence of ,food insecurity, , , TUESDAY, ... smokers are more likely to be underfed and undernourished, a ... members of smoking households, but children feel the impact the ... at New York University School of Medicine. , "We know ...
... 4 AlphaDetail, Inc. is growing.,As a leader ... to the Global Life Sciences Industry, the company ... senior staff members to its Professional,Services Group., ... based in,Alphadetail,s San Mateo, California headquarters office. Gloria ...
... Misonix, Inc.,(Nasdaq: MSON ), today announced that ... supplier of after market products, services,and test equipment ... study in Sweden at the country,s annual clinical ... was presented by the School,for Technology and Health, ...
... organs and other internal structures of the human body. ... that can predict the sound transmission of improved designs ... processing large quantities of data and can be run ... University Medical Centre and Oldelft Ultrasound are now using ...
... 2008) In the first-ever study of its kind, a ... Research Institute at Harbor-UCLA Medical Center (LA BioMed) report ... Hispanics took longer to respond to medication for depression ... English-speaking Hispanics. , Using data from the nation,s largest ...
... by nearly 100%, operating loss reduced by 44%, ... ), a leading provider of quantitative imaging for clinical,trials, ... 2008 were,over $1.8 million, a 33% increase over prior ... 30, 2008 were approximately $5.2,million compared to nearly $4.2 ...
Cached Medicine News:Health News:Smokers' Homes More Likely to House Hungry Kids 2Health News:Smokers' Homes More Likely to House Hungry Kids 3Health News:AlphaDetail, Inc. Continues Bi-coastal Expansion 2Health News:Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study 2Health News:Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study 3Health News:Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study 4Health News:Response rates to antidepressants differ among English- and Spanish-speaking Hispanics 2Health News:VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 2Health News:VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 3Health News:VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 4Health News:VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 5Health News:VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 6
... Endovenous Laser System is designed to help ... in the leg. Endovenous laser therapy is ... the treatment of varicose veins., In endovenous ... inserted into the varicosed vein, generally through ...
... high-power, long-pulse Nd:YAG technology provides practitioners with the ... lesions and perform permanent hair reduction on all ... size feature allows the practitioner to instantly switch ... spot size with a simple twist of the ...
...
...
Medicine Products: